Balancing innovation, access, and profits--market exclusivity for biologics
Engelberg, A.B.; Kesselheim, A.S.; Avorn, J.
New England Journal of Medicine 361(20): 1917-1919
2009
ISSN/ISBN: 0028-4793 PMID: 19828525 DOI: 10.1056/nejmp0908496
Accession: 051752936
Full Text Article emailed within 0-6 h: $19.90
Related References
Wheadon, D.E. 2010: Market exclusivity for biologics New England Journal of Medicine 362(7): 661; Author Reply 661-662Pollock, A.; Zagari, M. 2010: Market exclusivity for biologics New England Journal of Medicine 362(7): 661; Author Reply 661-662
Grabowski, H. 2008: Follow-on biologics: data exclusivity and the balance between innovation and competition Nature Reviews. Drug Discovery 7(6): 479-488
Kesselheim, A.S. 2010: Adalimumab pricing and market exclusivity for biologics New England Journal of Medicine 363(24): 2374
Gaudry, K.S. 2011: Exclusivity strategies and opportunities in view of the Biologics Price Competition and Innovation Act Food and Drug Law Journal 66(4): 587-630 Ii
Levi, E.Lawrence. 2017: Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes American University law review 66(3): 911-970
Fernandez, D.S.; Huie, J.T. 2004: Balancing US patent and FDA approval processes: strategically optimizing market exclusivity Drug Discovery Today 9(12): 509-512
Kesselheim, A.S. 2010: Using market-exclusivity incentives to promote pharmaceutical innovation New England Journal of Medicine 363(19): 1855-1862
Kraushaar, K.J. 1999: Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition Food and Drug Law Journal 54(2): 243-244
Xiao, Z.; He, D.; Du, J. 2021: A Stackelberg Game Pricing Through Balancing Trilateral Profits in Big Data Market IEEE Internet of Things Journal 8(16): 12658-12668
Morag-Sela, T.; Cohn, I.; Kowalski, T.J.; Jarecki-Black, J.; Clyde-Watson, Z. 2004: Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity Nature Biotechnology 22(12): 1591-1592
Shea, G. 2001: Balancing access and innovation Health Affairs 20(6): 308-309
Shea, G. 2001: Balancing Access and Innovation Health Affairs 20(6): 308-309
Hemphill, T.A. 2020: Biologics regulation, second-to-market competition, and the use of blockchain technology: an opportunity for the FDA to support responsible biotechnology innovation Journal of Responsible Innovation 7(3): 689-696
Grabowski, H.; Long, G.; Mortimer, R. 2011: Data exclusivity for biologics Nature Reviews. Drug Discovery 10(1): 15-16
Kozhemyakina, E; Kravit, A; Cox, J 2017: Sink or Swim: How Can Asthma Biologics Successfully Sail the Rough Waters of EU5 Market Access? Value in Health 20(9): A650-A651
Higgins, M.J.; Graham, S.J.H. 2009: Intellectual property. Balancing innovation and access: patent challenges tip the scales Science 326(5951): 370-371
Rajkumar, R.; Kesselheim, A.S. 2013: Balancing access and innovation: India's Supreme Court rules on imatinib JAMA 310(3): 263-264
Nicol, D. 2005: Balancing innovation and access to healthcare through the patent system--an Australian perspective Community Genetics 8(4): 228-234
Bouncken, R.B.; Fredrich, V.; Kraus, S.; Ritala, P. 2020: Innovation alliances: Balancing value creation dynamics, competitive intensity and market overlap Journal of Business Research 112: 240-247